Skip to main content
Toggle navigation
Search
Home
Icon Legend
This session is not in your schedule.
This session is in your schedule. Click again to remove it.
Presentation Icons
Red Recording
Sig Meeting
Like
Email
Tweet
Print
Brett Lauring, M.D., Ph.D.
Chief Medical Officer
Kallyope, Inc.
Poster(s):
(T 3) TRPM8 Channel Blockade with Elismetrep in a Phase 2B study: A Novel Approach for Treating Migraine
(T 6) In vitro Profile of Elismetrep: A Potent and Highly Selective Blocker of the Migraine-Associated Channel TRPM8
(T 34) The human pharmacokinetics of elismetrep, a TRPM8 migraine-associated channel blocker (MACB), are well-suited for a migraine therapeutic
(T 101) Exposure–response modeling predicts enhanced anti-migraine efficacy of elismetrep with an optimized formulation enabling faster drug absorption
Email Brett
